Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Agenus Are Breaking Out Today

By George Budwell - Jan 21, 2016 at 12:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock finally has a strong day after the drugmaker announces the FDA clearance of two IND applications for its immuno-oncology platform.

What: Shares of the small-cap immunotherapy company Agenus (AGEN 11.24%) woke up from their winter hibernation today, gaining more than 24% in early trading on heavy volume. The spark behind this sudden upward move was the news that the U.S. Food and Drug Administration cleared the company's investigational new drug (IND) applications for AGEN1884 and INCAGN1876.

AGEN1884 is an immune checkpoint modulator antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4), and is being developed directly by Agenus. INCAGN1876, on the other hand, is another checkpoint modulator antibody targeting the glucocorticoid-induced TNFR-related protein (GITR), and is being co-developed with Incyte (INCY 0.31%) as part of the two companies' global partnership in immuno-oncology.

So what: Agenus' share price has been in an absolute tailspin over the past six months because investors have seemingly lost their patience with the company's progress on the immuno-oncology front. According to data provided by S&P Capital IQ, for instance, the company's shares are currently down by over 62% from their 52-week highs -- even after today's surge upwards:

AGEN Chart

AGEN data by YCharts.

So, it's not entirely surprisingly that the company's stock is starting to rebound following this long-awaited clinical update. 

Now what: Agenus said in its press release that clinical trials for both compounds should begin in the first half of this year. Perhaps more important, though, the company expects to announce additional IND approvals for its broad immuno-oncology platform in the coming months. 

Looking ahead, Agenus may be able start receiving some much-needed cash from its deal with Incyte over the course of the year. After all, Agenus is reportedly eligible for up to $350 million in milestone payments under the terms of its global immuno-oncology partnership with Incyte. 

All told, Agenus is finally making strides toward catching up with its numerous peers in the red-hot field of immuno-oncology. I'm thus cautiously optimistic that the company's shares will start to recapture at least some of their former glory, making this speculative small-cap stock worth a closer look from seasoned biotech investors.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
$2.97 (11.24%) $0.30
Incyte Corporation Stock Quote
Incyte Corporation
$73.99 (0.31%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.